The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
QoL analysis: A randomized phase 3 study of sequential versus combination treatment in first-line chemotherapy for metastatic colorectal cancer—The C-cubed study.
 
Shingo Noura
No Relationships to Disclose
 
Ryo Inada
No Relationships to Disclose
 
Hitoshi Ojima
No Relationships to Disclose
 
Takeshi Nagasaka
No Relationships to Disclose
 
Hiroaki Tanioka
No Relationships to Disclose
 
Yoshinori Munemoto
No Relationships to Disclose
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - MSD K.K (Inst); Taiho Pharmaceutical (Inst)
 
Keiichiro Ishibashi
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Hideyuki Mishima
No Relationships to Disclose
 
Yoshiyuki Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Miyarisan Pharmaceutical; MSD; Ohara Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Kirin (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masazumi Okajima
No Relationships to Disclose